All In Biotech

Drug Trial Radar · NCT04672395

A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19

A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) for the Prevention of SARS-CoV-2- Mediated COVID-19 in Participants Aged 12 Years and Older

Last checked: Nov 19, 2026Latest source record: Jun 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 31,454 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

31,454

Actual

Start

Mar 24, 2021

Primary completion

Sep 15, 2022

Study completion Apr 23, 2023

Sponsor

Sponsor type
Industry
Collaborators
Coalition for Epidemic Preparedness Innovations; International Vaccine Institute
First posted
Dec 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this double-blind, randomized, controlled study is to evaluate the efficacy, immunogenicity, reactogenicity and safety of an adjuvanted recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) trimeric spike (S)-protein subunit vaccine (SCB-2019) for the prevention of SARS-CoV-2-mediated COVID-19 in Participants Aged 12 Years and Older.

Conditions

  • COVID-19

Interventions

  • CpG 1018/Alum-adjuvanted SCB-2019 vaccineBiological

    Group 1: Participants will receive 1 intramuscular (IM) injection of 30 microgram (ug) SCB-2019 with CpG1018/Alum adjuvant on Day 1 and on Day 22

  • Placebo; 0.9% salineBiological

    Group 2: Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 1 and on Day 22

  • SCB-2019 vaccineBiological

    Participants will receive 1 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant

  • SCB-2019 vaccine for PlaceboBiological

    Participants will receive 2 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant, 21 days apart

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with a First Occurrence of COVID-19 of Any Severity Starting 14 Days after Second Dose of SCB-2019Time frame: Day 36 up to Day 389 (1 year after second dose)
  2. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Time frame: Up to Day 8 (7 days after first dose) and up to Day 29 (7 days after second dose)
  3. Number of Participants with Unsolicited AEsTime frame: Up to Day 43 (21 days after each dose)
  4. Number of Participants with Serious Adverse Events (SAEs), or Medically Attended AEs (MAAEs), or AEs Leading to Early Termination, or Adverse Events of Special Interest (AESIs)Time frame: Up to Day 389 (1 year after second dose)
  5. Non-inferiority of the neutralizing titers after third dose compared to the neutralizing titers after second doseTime frame: 14 days after third dose
  6. Non-inferiority of the neutralising titers in adolescents versus young adults.Time frame: 14 days after second dose

Locations

31 sites in 5 countries. Site status is shown where the registry gives one.

  • Anima

    Alken, Belgium

  • Hôspital Erasme

    Brussels, Belgium

  • Private Practice RESPISOM Namur

    Namur, Belgium

  • Instituto D'OR de Pesquisa e Ensino

    Rio de Janeiro, Rio Do Janeiro, Brazil

  • Instituto Atena de Pesquisa Clinica

    Natal, Rio Grande do Norte, Brazil

  • CPCLIN - Centro de Pesquisas Clínicas de Natal

    Natal, Rio Grande do Norte, Brazil

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital da Universidade Federal de Santa Maria CEP/UFSM

    Santa Maria, Rio Grande do Sul, Brazil

  • Centro de Atención e investigación Médica S.A.S, CAIMED S.A.S - sede, Acacias

    Acacías, Colombia

  • Centro de Atención e investigación Médica S.A.S, CAIMED S.A.S - sede Aguazul

    Aguazul, Colombia

  • Clínica de la Costa Ltda

    Barranquilla, Colombia

  • Fundación Hospital Universitario del Norte

    Barranquilla, Colombia

  • Centro de Atención e investigación Médica S.A.S, CAIMED S.A.S - sede, Bogotá D.C.

    Bogotá, Colombia

  • Policlinico Social del Norte

    Bogotá, Colombia

  • Centro de Estudios en Infectología Pediátrica S.A.S. - CEIP S.A.S.

    Cali, Colombia

  • IPS Médicos Internistas de Caldas SAS

    Manizales, Colombia

  • Centro de Atención e investigación Médica S.A.S, CAIMED S.A.S - sede, Yopal

    Yopal, Colombia

  • Asian Hospital and Medical Center

    City of Muntinlupa, Philippines

  • St. Luke's Medical Center

    City of Taguig, Philippines

  • Las Pinas Doctors Hospital

    Las Piñas, Philippines

  • Tropical Disease Foundation

    Makati, Philippines

  • Manila Doctors Hospital

    Manila, Philippines

  • University of the Philippines Manila - Philippine General Hospital

    Pasay, Philippines

  • UERM Memorial Medical Center

    Quezon City, Philippines

  • University of the East Ramon Magsaysay Memorial Medical Center

    Quezon City, Philippines

  • FEU-NRMF Medical Center

    Quezon City, Philippines

  • De La Salle Medical and Health Sciences Institute

    Dasmariñas, Cavite, Philippines

  • Wits Clinical Research

    Johannesburg, Gauteng, South Africa

  • DJW Research

    Krugersdorp, Gauteng, South Africa

  • Soweto Clinical Trials Centre

    Soweto, Gauteng, South Africa

  • Dr JM Engelbrecht Trial Site

    Somerset West, Western Cape, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.